Support: 888-992-3836 Home NewsWire Subscriptions
InvestorsHub Logo
Login/Register
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Context Therapeutics Inc (CNTX)

  7. Context Therapeutics Inc (CNTX) News

CNTX

Context Therapeutics Inc

1.01
0.14 (16.09%)
Upgrade to Real-Time
Company Name Stock Ticker Symbol Market Type
Context Therapeutics Inc CNTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
Upgrade Icon
0.14 16.09% 1.01 18:33:38
Open Price Low Price High Price Close Price Prev Close
0.87 0.84 1.06 1.06 0.87
more quote information »

Recent News

Date Time Source Heading
6/01/20237:35IHNWFeaturedNew Break Announces Closing of $500,700 Non-Brokered Flow-Through Financing
5/31/202316:53EDGARStatement of Changes in Beneficial Ownership (4)
5/10/202316:39GLOBEContext Therapeutics Reports First Quarter 2023 Operating..
4/03/202307:30GLOBEContext Therapeutics to Participate in Two April 2023..
3/27/202316:04EDGARProxy Statement - Notice of Shareholders Meeting..
3/22/202317:10EDGARCurrent Report Filing (8-k)
3/22/202317:08GLOBEContext Therapeutics Reports Full Year 2022 Financial..
3/15/202307:30GLOBEContext Therapeutics Announces Acceptance of Abstract to be..
2/14/202317:26EDGARStatement of Changes in Beneficial Ownership (4)
2/14/202317:26EDGARStatement of Changes in Beneficial Ownership (4)
2/14/202317:25EDGARStatement of Changes in Beneficial Ownership (4)
2/14/202316:05EDGARStatement of Ownership (sc 13g)
2/13/202316:04EDGARStatement of Changes in Beneficial Ownership (4)
2/06/202316:04EDGARStatement of Changes in Beneficial Ownership (4)
2/06/202307:30GLOBEContext Therapeutics Highlights Clinical Responses from the..
1/31/202307:30GLOBEContext Therapeutics’ Clinical Partner Stemline..
1/30/202316:05EDGARStatement of Changes in Beneficial Ownership (4)
1/27/202316:03EDGARCurrent Report Filing (8-k)
1/23/202317:04EDGARStatement of Changes in Beneficial Ownership (4)
1/09/202307:30GLOBEContext Therapeutics and Lonza Enter Manufacturing Agreement..
1/04/202307:33EDGARCurrent Report Filing (8-k)
1/04/202307:30GLOBEContext Therapeutics® Highlights 2023 Corporate Priorities..
12/19/202216:23EDGARStatement of Changes in Beneficial Ownership (4)
12/19/202216:11EDGARStatement of Changes in Beneficial Ownership (4)
12/12/202216:16EDGARStatement of Changes in Beneficial Ownership (4)
12/08/202211:35TRMNH.C. Wainwright Sticks to Their Buy Rating for Context..
12/08/202207:33EDGARCurrent Report Filing (8-k)
12/08/202207:30GLOBEContext Therapeutics® Reports Encouraging Preliminary Phase..
12/02/202206:15TRMNContext Therapeutics (CNTX) Receives a Buy from H.C...
12/01/202208:03EDGARCurrent Report Filing (8-k)
11/29/202207:30GLOBEContext Therapeutics® Nominates CTIM-76 Bispecific Antibody..
11/21/202209:11GLOBEContext Therapeutics® Announces Clinical Updates on ONA-XR..
11/14/202216:22EDGARProspectus Filed Pursuant to Rule 424(b)(3) (424b3)
11/14/202206:07EDGARNotice of Effectiveness (effect)
11/10/202206:17TRMNH.C. Wainwright Remains a Buy on Context Therapeutics (CNTX)
11/09/202216:37EDGARPost-effective Amendment to Registration Statement (pos Am)
11/09/202216:37EDGARSecurities Registration Statement (simplified Form) (s-3)
11/09/202216:16EDGARCurrent Report Filing (8-k)
11/09/202216:14GLOBEContext Therapeutics® Reports Third Quarter 2022 Operating..
10/27/202213:23EDGARStatement of Ownership (sc 13g)
9/27/202211:55TRMNH.C. Wainwright Sticks to Their Buy Rating for Context..
9/27/202207:41EDGARProspectus Filed Pursuant to Rule 424(b)(3) (424b3)
9/27/202207:39EDGARCurrent Report Filing (8-k)
9/27/202207:30GLOBEContext Therapeutics® Amends Cash Guidance, Extends Runway..
9/06/202207:30GLOBEContext Therapeutics® to Participate in the H.C. Wainwright..
8/22/202216:05EDGARStatement of Changes in Beneficial Ownership (4)
8/17/202217:23EDGARStatement of Changes in Beneficial Ownership (4)
8/12/202216:32EDGARStatement of Changes in Beneficial Ownership (4)
8/12/202206:26TRMNH.C. Wainwright Reaffirms Their Buy Rating on Context..
8/11/202216:41EDGARProspectus Filed Pursuant to Rule 424(b)(3) (424b3)
8/11/202216:05EDGARQuarterly Report (10-q)